trending Market Intelligence /marketintelligence/en/news-insights/trending/x52XAL146lYbdysUlvehHg2 content esgSubNav
In This List

Sucampo upsizes note offering to $260M

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Sucampo upsizes note offering to $260M

Sucampo Pharmaceuticals Inc. priced and upsized a previously announced debt offering to repay an existing senior secured credit facility.

The company will issue $260 million worth of 3.25% senior notes due 2021, complete with an option to purchase an additional $40 million worth of the debt.

Interest will be payable semiannually starting June 15, 2017. The notes will also convert into class A Sucampo shares at an initial conversion rate of $16.59 per share.

Sucampo initially planned on issuing $225 million of the debt.

Sucampo Pharmaceuticals secured a $250 million credit facility in October 2015 to fund its planned purchase of R-Tech Ueno. The new debt issue could help free up some of the company's cash, given that Sucampo is required to maintain at least $25 million in a restricted cash account until at least $35 million of the facility is repaid or prepaid.

Leerink Partners LLC is the sole book-running manager of the issue. The sale is expected to close Dec. 27.